

1 Dalmore Drive,
Scoresby,
Victoria 3179
AUSTRALIA
T: +61 (0)3 9763-1287
F: +61 (0)3 9763-2817
www.generabiosystems.com

Monday 21 November 2016

**ASX Announcement – GENERA BIOSYSTEMS LIMITED (ASX: GBI)
GENERA RECEIVES R&D TAX REBATE**

Genera Biosystems Limited (**‘Genera’**) is pleased to advise that the Company has received an R&D tax Incentive refund of \$722k for the 2015/16 financial year. The \$30k variance between the final amount received and the amount guided to on Genera’s 15 November ASX release reflects a debit that was netted off by the ATO on the Company’s tax portal account.

The R&D tax Incentive is an Australian Government program under which companies with turnover of less than \$20m receive a cash refund for 45% of eligible expenditure on research and development.

With the earlier than anticipated receipt of these funds Genera will not issue the final \$125k tranche of Series B Convertible Notes as provided for in the original Series B Note Deed. As such the final face value of Series B Convertible Notes issued by the Genera will be \$2.875m. The conversion price of the Series B Notes, largely issued in late 2014, is \$0.23.

Genera currently anticipates announcing the quantum of the proposed Series C financing within the next 10 days.

For further information please contact:

Mr Richard Hannebery
Chief Executive Officer
Genera Biosystems Limited
Telephone: +61 (0)3 9763 1287
www.generabiosystems.com.au

About Genera Biosystems : Genera Biosystems Limited (“GBI”) is an Australian Securities Exchange listed molecular diagnostics company, which develops, manufactures and distributes advanced PCR molecular diagnostics tests. GBI has successfully developed two products to date, PapType® and RTI-Plex™, both of which are CE marked with several additional products in the company’s development pipeline. Genera manufactures these products in its Therapeutics Goods Administration (TGA) certified manufacturing facility in Scoresby, Victoria, Australia.